The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Allergen extract from tree pollen for sublingual use (V01AA05);

Allergen extract from grass pollen for sublingual use (V01AA02);

Allergen extract from house dust mites for sublingual use (V01AA03);

Allergen extracts from tree pollen, grass pollen or house dust mites for subcutaneous use

(V01AA02, V01AA03, V01AA05);

Candesartan & amlodipine (C09DB07);

Dienogest (G03DB08);

Dienogest & ethinylestradiol (G03AA16);

Permethrin (P03AC04).

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations, subject to standardized contractual conditions and a standardized access procedure.

The earliest contract start is April 1st, 2021. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is April 1st, 2021. Based on this, the contract term is a maximum of 24 months.